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Results: Mean percentage of IDDs with >95% pass rate for 1mm/1% criteria were 96.7% (SD 4.9) for XiO®, 94.1% (SD 8.9) for EclipseTM, 95.4% (SD 8.6) for RayStation®, and 49.2 (SD 26.0) for Pinnacle3. Maximum differences between computed and measured IDD data are shown below. No correlation with nominal energy was observed.
Conclusion: Characteristics of computed IDDs were compared to measured data for four commercially available TPSs. All were within clinically acceptable tolerances, with XiO showing the closest agreement. Differences observed were attributed to TPS specific beam modelling. Further investigation will assess the cumulative impact of these discrepancies on verified clinical treatment plans. Purpose or Objective: One of the clinical issues our institute faces regarding in vivo EPID dosimetry is the number of raised alerts. For example, alerts are raised for 49% of the treatments in case of head-and-neck (H&N) VMAT treatments; an alert is raised when dosimetry results are found deviating according to statistics derived from the histogram of 3D γ-analysis results. These alerts are mostly found to be patient-related or attributable to limitations of our back-projection and dose calculation algorithm. After inspection, an intervention is considered for only 0.3% of the treatments. The purpose of this study is to develop a principal component analysis (PCA) based classification method to improve the specificity of our EPID dosimetry system. In particular, in contrast to our current classification method, PCA allows for the spatial distribution of γ-values to be taken into account for deviation detection.
PO-0827 Principal component analysis for deviation detection in 3D in vivo EPID dosimetry

Material and Methods:
The input for PCA consisted of 3D γdistributions (3%/3mm), one per treatment arc per fraction. In total, 2024 3D γ-distributions from 499 H&N VMAT treatment-plans were included. As an initial choice, components describing at least 1% of the variance were selected. The distribution of variances over the components was inspected to validate this choice. Using these components, new 3D γ-distributions were created by projecting each input 3D γ-distribution on only these components and then projecting the result to the original coordinate system of the 3D γ-distributions. If the selected components describe the original γ-distribution well, the new and original γ-distributions will be similar. This similarity was quantified by the root mean square (RMS) d of the difference between the two γ-distributions; a γ-distribution was marked as deviating when d exceeded a threshold. All true positive γdistributions (n = 2) in the dataset, as identified by experienced medical physicists, were used to determine this threshold for identification of alerts.
Results: The first 16 components were each found to describe at least 1% of the variance; cumulatively, they account for 83% of the variance in the dataset. Figure 1 shows the cumulative variance accounted for as a function of selected components and indicates that the choice for selecting components is reasonable. After finding and applying the appropriate threshold for detecting the identified true positives, a drop in alert rate from 49% to of 11% was observed, corresponding to an increase in specificity from 0.51 to 0.89.
Conclusion:
The PCA-based classification method presented in this study enhances the specificity of deviation detection in 3D in vivo EPID dosimetry of H&N VMAT from 0.51 to 0.89, compared to our current clinical γ-histogram based method. Before clinical implemention, a rigorous validation is required. Recently, a second generation Multi-Leaf Collimator (InCise 2™) was released for the CyberKnife® M6™ robotic radiotherapy system. As part of the evaluation and initial characterization, physical, dosimetric and planning parameters were recorded. Further, planning studies on phantoms were performed to compare the InCise 2 to the Iris™ collimator system.
PO-0828 Dosimetric assessment of a second generation Multi-Leaf
Material and Methods:
As part of the InCise 2 validation, leakage, TG-50 picket fence, Bayouth fence and automated quality assurance measurements were performed using radiochromic film. End to end delivery tests were performed for skull-, fiducial-, x-sight spine-, x-sight lung-and synchrony tracking. Ten treatment plans and five QA plans were delivered to phantoms using the InCise 2. Ionization chamber measurements as well as film measurements were compared with dose calculated by the treatment planning system. For dosimetric assessment, treatment plans to water phantoms were generated using the IRIS collimator system and the InCise 2 MLC. On a cylindrical water phantom of a diameter of 20 cm, spherical target volumes of diameters from 5 to 80 mm were drawn. Firstly, the dose optimization algorithm using the MLC was assessed using a simple Optimize Minimum Dose (OMI) objective. Secondly, shell volumes were generated around the target volumes and their coverage was optimized (OCI). 1000 cGy were prescribed to the 80% isodose. Dose distributions, Nakamura's new Conformity Index (nCI) as well as optimization and estimated treatment times were analyzed.
Results: All validation tests were passed within tolerances. Maximum leakage was recorded as 0.44% for all MLC orientations. Mean leaf positioning errors in Bayouth fence tests ranged from -0.043 mm to 0.006 mm, without any individual leaves exceeding the tolerance of ±0.27 mm. All phantom plans were delivered successfully, with recorded dose for QA plans differing 1.94% ±1.03% from calculated dose and gamma analysis (3% / 1mm, 20% dose threshold) showing > 97% agreement. Total end to end tracking errors were below 0.95 mm for all tested tracking methods. Testing the optimization algorithm revealed nCI values for plans optimized based on target volume shells between 1.02 and 1.50 for plans using the InCise 2 and 1.05 and 1.43 for IRIS. MLC optimization times increased as a function of both target size and optimization steps, ranging from 12 s for the 5 mm PTV OMI plan to 7 h for the 80 mm PTV shell based optimization. Estimated treatment times including setup times for the synthetic plans were reduced by a mean of 19.1% when choosing the InCise 2 over the IRIS.
Conclusion:
The InCise 2 MLC system passed initial physics evaluation at our site and showed dose distributions comparable to the CyberKnife IRIS collimator system for spherical targets. Estimated MLC treatment times are about 20% lower compared to the IRIS collimator system.
